Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: An exploratory analysis

Arthritis and Rheumatism

Volumn 56, Issue 2, 2007, Pages 688-692

  Chollet Janin, Amélie ^a   Finckh, Axel ^a   Dudler, Jean ^b   Guerne, Pierre André ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM PYROPHOSPHATE; COLCHICINE; FOLIC ACID; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; AGED; ARTICLE; CHONDROCALCINOSIS; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; ONSET AGE; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PSEUDOGOUT; SECONDARY HYPERPARATHYROIDISM; STOMATITIS; SWITZERLAND; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CHONDROCALCINOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847055422     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22389     Document Type: Article

References (15)

1. 1) in pathologic calcification of articular cartilage [review]. Front Biosci 2005;10:988-97.
2. Zhang Y, Brown MA. Genetic studies of chondrocalcinosis [review]. Curr Opin Rheumatol 2005;17:330-5.
3. Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol 2005;17:314-8.
4. Cheung HS. Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol 2000;12:223-7.
5. Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 1986;13:804-5.
6. McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease: nomenclature and diagnostic criteria. Ann Intern Med 1977;87:241-2.
7. Cheung HS. Biologic effects of calcium-containing crystals [review]. Curr Opin Rheumatol 2005;17:336-40.
8. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72.
9. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity [review]. Trends Immunol 2004;25:33-9.
10. Seitz M. Molecular and cellular effects of methotrexate [review]. Curr Opin Rheumatol 1999;11:226-32.
11. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabandi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin [published erratum appears in Arthritis Rheum 1993;36:1028]. Arthritis Rheum 1993;36:613-9.
12. Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J 2000;76:787-9.
13. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
14. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005;64:207-11.
15. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.